“We have proof-of-principle evidence showing the feasibility of small-molecule modulation of costimulatory interaction which, ultimately, could become relevant for the treatment of autoimmune diseases and transplant patients.”
Peter Buchwald, Ph.D.
Peter Buchwald, Ph.D., is an Associate Professor in the Department of Molecular and Cellular Pharmacology at the University of Miami Miller School of Medicine and the Director of the Drug Discovery Program at the Diabetes Research Institute.
Dr. Buchwald obtained his doctorate from the University of Florida. He has worked in multi-disciplinary fields related to drug design and development both in the academic and industrial settings.
Dr. Buchwald has published numerous articles in peer-reviewed journals focused on the physicochemical and metabolic aspects of drug design and drug action, as well as on computer-aided quantitative modeling.
Coming from the pharmaceutical industry, Dr. Buchwald is directing the DRI’s efforts aimed at developing safer and more effective drugs for islet replacement therapies.
Interview: Under the Microscope
Small-Molecule Inhibitors of the CD40-CD40L Costimulatory Protein-Protein Interaction
Scientists identify new biochemical “signature” as potential early indicator of T1D onset
Scientific Society Honors DRI Researcher
Researchers awarded grants for treatments and cures
View publications on Google Scholar